Segment Reporting - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) Segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021
Number of operating segments | Segment			1
Accounts receivable, percentage by customer	100.00%	100.00%	100.00%	100.00%
Revenue	$ 200,741,000	$ 178,216,000	$ 614,774,000	$ 484,013,000
Sales Revenue
Revenue			$ 0	$ 0
Customer Concentration Risk | Pfizer [Member]
Revenue	$ 19,100,000	$ 19,100,000
Customer Concentration Risk | Sales Revenue | Minimum [Member]
Accounts receivable, percentage by customer			10.00%	10.00%
Customer Concentration Risk | Sales Revenue | Pfizer [Member]
Accounts receivable, percentage by customer	11.00%	11.00%
Customer Concentration Risk | Sales Revenue | Pfizer [Member] | Minimum [Member]
Accounts receivable, percentage by customer	10.00%	10.00%
Customer Concentration Risk | Accounts Receivable [Member] | Pfizer [Member]
Accounts receivable, percentage by customer					14.00%
Customer Concentration Risk | Accounts Receivable [Member] | Customer Number One [Member]
Accounts receivable, percentage by customer			10.00%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Pfizer [Member]
Accounts receivable, percentage by customer					10.00%